



Ind-Swift LABORATORIES LIMITED

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553



Ref.:ISLL:CH:2016

Date: 11th November, 2016

The General Manager,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Manager,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No.C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

Subject: Compliance of Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.

Dear Sir,

Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015, this is to inform the Exchange that the Board of Directors in its meeting held today i.e. 11th November, 2016 have taken on record/approved inter-alia the following: -

1. Quarterly Un-audited Financial Results (provisional) for the quarter and half year ended 30th September, 2016 along with Limited Review Certificate of Statutory Auditors of the Company (Copy Enclosed).
2. Allotment of 32,57,166 Equity shares to the Promoters and Promoter Group Companies on preferential basis at a price of Rs. 55.50/- each (including premium) as under:
 - i) 16,77,476 shares against IInd Tranche of Promoters' Contribution in terms of CDR package of the Company.
 - ii) 4,05,405 shares against part receipt of funds under IIIrd Tranche of Promoters' Contribution in terms of CDR package of the Company.
 - iii) 11,74,285 shares against IIIrd Tranche of Promoters' Contribution in terms of CDR package of the Company.

You are requested to kindly take a record of the same.

Thanking you,
For IND-SWIFT LABORATORIES LTD.

PARDEEP VERMA
GM-CORPORATE AFFAIRS &
COMPANY SECRETARY

IND SWIFT LABORATORIES LTD.

Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160 101

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th, Sept 2016

CIN L24232CH1995PLC015553

(Rs. in Lacs)

Particulars	Quarter Ended 30.09.2016	Quarter Ended 30.06.2016	Quarter Ended 30.09.15	Half Year Ended Sept 2016	Half Year Ended Sept 2015	Year Ended 31.03.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income from Operations:						
(a) Net Sales/Incomes from Operations	16641.15	17507.23	16092.27	34148.38	33061.20	63874.40
(b) Other Operating Income	370.57	392.24	282.19	62.81	646.18	1418.47
Total Net Sales / Operating Income	17011.72	17899.47	16374.47	34911.18	33707.38	65292.86
EXPENSES:						
a Cost of Materials Consumed	8120.95	8783.15	9049.11	16904.10	18155.64	33753.87
b.Purchase of stock in Trade	127.75	88.73	55.22	216.48	171.31	582.63
c.(Increase)/decrease in FG,WIP & stock in trade	896.01	617.73	181.71	1513.74	985.87	91.08
d. Staff cost	1783.18	1789.96	1596.96	3573.14	3001.55	6482.41
e. Depreciation	2201.95	2188.40	2141.43	4390.35	4232.28	8474.88
f. Other expenditure	2931.37	3611.66	2664.96	6543.03	5805.68	12122.69
TOTAL EXPENSES	16061.21	17079.63	15689.38	33140.84	32352.32	61507.55
Profit(loss) from Operations before Other Income, finance cost & Exceptional Items	950.50	819.83	685.08	1770.34	1355.06	3785.32
Misc Income	0.00	0.00	0.00	0.00	0.00	0.00
Profit(Loss) before Interest & Exceptional Items	950.50	819.83	685.08	1770.34	1355.06	3785.32
Interest	2258.46	2412.47	2573.68	4670.93	5192.87	10800.55
Previous year income/expenses	269.72	14.20	27.57	283.91	29.69	52.90
Forex Fluctuation Expenditure/(income)	(134.79)	66.42	(346.38)	(68.36)	(665.51)	(159.77)
Profit(Loss) after Interest but before Exceptional Items	(1442.88)	(1673.26)	(1569.79)	(3116.14)	(3201.99)	(6908.36)
Exceptional Items	0.00	0.00	0.00	0.00	0.00	1405.26
Profit (+)/ Loss (-) from Ordinary Activities before tax	(1442.88)	(1673.26)	(1569.79)	(3116.14)	(3201.99)	(8313.62)
Provision for deferred Tax	0.00	0.00	0.00	0.00	0.00	(2427.51)
Net Profit / (Loss) for the period after Tax	(1442.88)	(1673.26)	(1569.79)	(3116.14)	(3201.99)	(5886.11)
Provision for dividend on Equity Shares						
Provision for Equity dividend Tax						
Transfer to General reserve						
Retained Profit / (Loss)	(1442.88)	(1673.26)	(1569.79)	(3116.14)	(3201.99)	(5886.11)
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	4148.25	4096.32	4096.32	4148.25	4096.32	4096.32
Reserve excluding revaluation reserves						18887.80
EPS (of Rs. 10/- each) (Not annualised)						
Basic	(3.52)	(4.08)	(3.83)	(7.61)	(7.82)	(14.37)
Diluted	(3.52)	(4.08)	(3.83)	(7.61)	(7.82)	(14.37)
Notes: -						
1. Under the provisions of the Companies Act, 1956, the Company has got its Fixed Deposit Scheme restructured vide its order No. C.P 27/01/2013, Dated 30.09.2013 through Hon'ble Company Law Board. The Company has been granted extension of time in repayment						
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 11th, November 2016						
3. The previous period figures have been re-grouped and re-arranged wherever necessary.						
4. The Company is exclusively in the Pharmaceutical Business segment.						
5 The Company has approved the allotment of 32,57,166 Shares under Second and Third Tranche of the Promoters Contribution pursuant to the CDR package of the Company in its meeting held on 11th November, 2016.						
					For Ind-Swift Laboratories Limited	
					<i>NR Munjai</i>	
Place : Chandigarh					NR Munjai	
Date : 11.11.2016					Vice Chairman cum MD	

For Ind-Swift Laboratories Ltd.
Pardeep Verma
 (Pardeep Verma)
 GM-Corporate Affairs & Company Secretary

The Standalone Statement of Assets and liabilities is as under :-		
	As at	As at
	30.09.2016	31.03.2016
	Unaudited	Audited
I.EQUITY AND LIABILITIES	₹ in lacs	
(1) Shareholders' Funds		
a)Share Capital	4220.14	4168.22
b)Reserves & Surplus	44580.14	47300.54
(2) Non-current liabilities		
(a) Long-term borrowings	71770.82	74632.82
(3.) Current Liabilities		
(a) Short term Borrowings	50986.88	50365.69
(b)Trade Payables	13879.22	12945.07
(c) Other current liabilities	33331.87	31608.87
Total Equity & Liabilities	218769.08	221021.21
II.ASSETS		
Non-Current Assets		
(1) (a) Fixed Assets		
(i) Tangible Assets	83812.93	87969.48
(ii) Intangible Assets	21905.98	21575.98
(iii) Capital work in Progress (Tangible)	7258.81	6588.12
(iv) Capital work in Progress (Intangible)	1395.51	1258.48
(v) Assets held for disposal	306.25	306.25
Net Block	114679.48	117698.31
(b) Non-Current investment	2641.66	2637.66
(c) Defferred Tax Assets(Net)	2908.57	2908.57
(d) Long-term loans & advances	7763.12	6892.13
(2) Current assets		
(a) Inventories	36034.40	35601.73
(b) Trade receivables	34960.28	35881.93
(c) Cash and cash equivalent	3102.22	2142.88
(d) Short-term loans and advances	16679.34	17257.99
Total Assets	218769.08	221021.21

For Ind-Swift Laboratories Ltd.

Pardeep Verma
(Pardeep Verma)
GM-Corporate Affairs & Company Secretary

JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

S.C.O. 819-20, Sector-22 A, Chandigarh 160 022
Phone: 0172-2705761, 2701629 Fax: 0172-5089769
Email :jainassociates1968@gmail.com

JA/SCP/2016-17/77

LIMITED REVIEW

The Board of Directors
Ind-Swift Laboratories Ltd.
S.C.O. 850, NAC Manimajra
Chandigarh

We have reviewed the accompanying statement of unaudited financial results of Ind-Swift Laboratories Ltd for the Quarter ended 30.09.2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on review Engagement (SRE) 2400 , Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India . This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement . A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit . We have not performed an audit and accordingly, we do not express such an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement .


FOR JAIN & ASSOCIATES
Chartered Accountants
(Regd.No.001361N)


(S.C.PATHAK)
Partner

Membership No 10194

Place: Chandigarh
Date : 11.11.2016

For Ind-Swift Laboratories Ltd.



(Pardeep Verma)
GM-Corporate Affairs & Company Secretary